publication date: Dec. 9, 2010

In this issue: 

ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.

ODAC Member Critical Of Amgen For Price Incentives.

Amgen, J&J Defend ESA Indications.

ODAC Recommends Approval Of Nplate For Thrombocytopenia.

Funding Opportunities: HHMI Commits $300M To Support Early Career Scientists.

Download (PDF 494KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.